The Huntington Society of Canada (HSC) plays a key role in connecting researchers, clinicians, and individuals affected by Huntington disease (HD) by educating Canadians on the importance of clinical trials and participation. Efforts focus on reaching diverse and rural communities while ensuring sustainable support for clinicians. HSC is emerging as a leader in trial preparedness, as current drug trials are specifically designed for HD, marking significant progress. Managing HD requires collaboration among researchers, clinicians, HSC, and HD families. We all have to work together. It is our best chance for success.
Frequency of Selected Single Nucleotide Polymorphisms in Huntington Disease Gene Expansion Carriers
ENROLL-HD: an observational study for HD families that monitors how HD appears and changes in people over time. The study’s overarching goal is to accelerate the discovery and development of new therapeutics through a better understanding of HD
HDClarity: an observational study; Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for HD
A study to evaluate ALN-HTT02 in adult patients with Huntington’s Disease
INVEST-HD: A study to investigate the efficacy, safety and tolerability of votoplam in participants with Huntington’s disease
FALCON-HD: Study to Evaluate the Pharmacodynamics, Safety and Efficacy of SKY-0515 in Participants With Huntington’s Disease
PRECISE-HD: A Phase 3 Study of Pridopidine in Huntington’s disease
HDSA’s HD Trialfinder connects individuals with HD, caregivers, volunteers, and physicians to current research studies through an easy-to-use website and free call center. Users can create a profile to match with trials or browse ongoing studies without providing personal information.
Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With HD.
GENERATION HD1: a Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington’s Disease.
DIMENSION: a Phase 2 study offered by Sage Therapeutics, Inc. investigated SAGE-718 for the treatment of cognitive symptoms associated with HD in adults with premanifest or early manifest HD.
PURVIEW: a Phase 3 Open-Label extension study offered by Sage Therapeutics, Inc. evaluated the safety and tolerability of SAGE-718 in adults with HD for those who completed the DIMENSION study.
GENERATION HD2: a Phase 2 study evaluated the safety, efficacy and biomarkers of tominersen in participants with prodromal and early manifest HD.
SELECT-HD: a Phase 1b/2a study evaluated the safety, tolerability, PK, and PD of WVE-003 in adult patients with early-manifest HD who carry the targeted single nucleotide polymorphism (SNP) – SNP3.
PIVOT-HD: a Phase 2 study offered by PTC Therapeutics, Inc. evaluated the safety and pharmacodynamics effects of PTC518 compared with placebo in participants with HD.
POINT-HD: A study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of RG6496 in Huntington’s disease.
